Hematologic Malignancy
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CI-CAN-00000765Explore in graph →
Hematologic298 active trials6 approved drugs47 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000765Explore in graph →
Clinical trials
1,406 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (273)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | terminated | N/A | 200 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03919214 | Hypertension Management in Cancer Patients | terminated | N/A | 4 | Duke UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04595851 |
| Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications |
| terminated |
| N/A |
| 6 |
| University of Michigan Rogel Cancer CenterOTHER |
| 1 |
| Nov 22, 2022 |
| clinicaltrials |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | terminated | N/A | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | N/A | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01649791 | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia | terminated | N/A | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT00587847 | Campath Maintenance in Chronic Lymphocytic Leukemia | terminated | N/A | 12 | Northwell HealthOTHER | 1 | Oct 15, 2015 | clinicaltrials |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | terminated | N/A | 10 | Indiana UniversityOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | terminated | N/A | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | terminated | N/A | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2012 | clinicaltrials |
Data updated 22 days agoSource updated May 20, 2026source: clinicaltrials